Published in Lancet on June 03, 1989
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A (2003) 7.57
Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A (2008) 4.50
PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol (2007) 3.86
Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet (2010) 3.77
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci U S A (1994) 2.96
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A (1996) 2.88
The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron (2015) 2.82
Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci U S A (2008) 2.64
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol (2008) 2.34
Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol (1999) 2.31
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia. J Cell Biol (2003) 1.95
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia. Mol Cell Biol (1996) 1.76
A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem (2010) 1.75
The development of mitochondrial medicine. Proc Natl Acad Sci U S A (1994) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS One (2011) 1.62
Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A (2008) 1.61
Complex I deficiency in Parkinson's disease frontal cortex. Brain Res (2007) 1.61
Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One (2009) 1.59
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol (2010) 1.57
Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos Trans R Soc Lond B Biol Sci (2005) 1.55
Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J Neurochem (2009) 1.52
Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness? Exp Neurol (2012) 1.50
DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. Proc Natl Acad Sci U S A (2010) 1.49
Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer (2011) 1.45
The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.44
Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet (1997) 1.43
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal (2010) 1.40
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis (2012) 1.39
Redox imbalance in Parkinson's disease. Biochim Biophys Acta (2008) 1.39
A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med (2011) 1.36
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem (2011) 1.33
6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med (2007) 1.32
The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci (2011) 1.31
The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal (2009) 1.31
Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J Neurol (2008) 1.28
Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol (2011) 1.28
Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med (2008) 1.25
Mitochondrial dynamics in Parkinson's disease. Exp Neurol (2009) 1.24
TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta (2011) 1.22
Mitochondrial function in Parkinson's disease. Lancet (1989) 1.20
Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res Rev (2014) 1.17
Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics (2006) 1.16
Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol Dis (2010) 1.15
The neurodegenerative mitochondriopathies. J Alzheimers Dis (2009) 1.14
Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS One (2010) 1.14
Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol (2006) 1.14
PINK1 function in health and disease. EMBO Mol Med (2009) 1.14
Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum Mol Genet (2012) 1.13
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics (2010) 1.12
NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal (2012) 1.12
Metabolic profiles show specific mitochondrial toxicities in vitro in myotube cells. J Biomol NMR (2011) 1.10
Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis (2011) 1.10
Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One (2009) 1.09
Mitochondrial respiratory complex I: structure, function and implication in human diseases. Curr Med Chem (2009) 1.08
The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev (2015) 1.08
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma (2011) 1.08
Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease. J Bioenerg Biomembr (2009) 1.07
Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum Mol Genet (2011) 1.06
The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics. Int J Biochem Cell Biol (2009) 1.05
The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem (2010) 1.05
The role of mitochondria in neurodegenerative diseases. J Neurol (2011) 1.05
NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage. J Clin Invest (2015) 1.05
Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet (1998) 1.04
Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic Biol Med (2012) 1.04
Mitophagy programs: mechanisms and physiological implications of mitochondrial targeting by autophagy. Cell Mol Life Sci (2015) 1.03
Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol (2010) 1.01
Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron (2015) 1.00
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol Neurodegener (2010) 1.00
Products of the Parkinson's disease-related glyoxalase DJ-1, D-lactate and glycolate, support mitochondrial membrane potential and neuronal survival. Biol Open (2014) 1.00
Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology (2013) 1.00
DJ-1 deficiency in astrocytes selectively enhances mitochondrial Complex I inhibitor-induced neurotoxicity. J Neurochem (2011) 1.00
PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond. Prog Neurobiol (2011) 1.00
Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J Biol Chem (2014) 1.00
α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease. Free Radic Biol Med (2013) 0.99
Intracellular and extracellular redox status and free radical generation in primary immune cells from children with autism. Autism Res Treat (2011) 0.99
A mitocentric view of Parkinson's disease. Annu Rev Neurosci (2014) 0.99
Parkin deficiency results in accumulation of abnormal mitochondria in aging myocytes. Commun Integr Biol (2013) 0.99
The modern management of Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 0.99
Mitochondrial dynamics and Parkinson's disease: focus on parkin. Antioxid Redox Signal (2011) 0.99
Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. Neurobiol Aging (2013) 0.99
Mitochondrial quality control and neurological disease: an emerging connection. Expert Rev Mol Med (2010) 0.98
Mitochondria in neurodegeneration. Adv Exp Med Biol (2012) 0.97
Blocking c-Jun N-terminal kinase (JNK) translocation to the mitochondria prevents 6-hydroxydopamine-induced toxicity in vitro and in vivo. J Biol Chem (2012) 0.97
Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease. Neurobiol Aging (2013) 0.97
POLG1 polyglutamine tract variants associated with Parkinson's disease. Neurosci Lett (2010) 0.96
Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci (2009) 0.95
Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One (2009) 0.95
TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson's disease. PLoS One (2013) 0.95
Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice. Mitochondrion (2013) 0.94
PINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease. FEBS J (2014) 0.94
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
The Role of Peroxide in the Biological Effects of Irradiated Broth. J Bacteriol (1948) 6.42
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
The Production of Mutations in Staphylococcus aureus by Chemical Treatment of the Substrate. J Bacteriol (1947) 5.22
Servo action in the human thumb. J Physiol (1976) 4.93
Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77
Servo action in human voluntary movement. Nature (1972) 4.33
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Method of determining oxygen concentrations in biological media, suitable for calibration of the oxygen electrode. Anal Biochem (1970) 4.11
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Painful legs and moving toes. Brain (1971) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54
Writers' cramp-a focal dystonia. Brain (1982) 3.43
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41
Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet (1992) 3.30
Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29
Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26
Corticobasal degeneration. Brain (1989) 3.20
Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Classification of dystonia. Adv Neurol (1998) 2.75
Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72
Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Manual motor performance in a deafferented man. Brain (1982) 2.63
The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60
Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58
The Rôle of Mutation and of Selection in the Frequency of Mutants Among Microörganisms Grown on Irradiated Substrate. Proc Natl Acad Sci U S A (1948) 2.55
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54
Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The pathophysiology of primary dystonia. Brain (1998) 2.51
Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40
A study of hereditary essential tremor. Brain (1994) 2.37
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37
The metabolism of rat brain mitochondria. Preparation and characterization. J Biol Chem (1970) 2.37
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36
Disturbance of sequential movements in patients with Parkinson's disease. Brain (1987) 2.30
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30
Abnormalities in central motor pathway conduction in multiple sclerosis. Lancet (1984) 2.30
Isolated single motor units in human muscle and their rate of discharge during maximal voluntary effort. J Physiol (1971) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Delay in the execution of voluntary movement by electrical or magnetic brain stimulation in intact man. Evidence for the storage of motor programs in the brain. Brain (1989) 2.19
Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport (1996) 2.18
The sensory mechanism of servo action in human muscle. J Physiol (1977) 2.18
Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry (1976) 2.18
Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet (1997) 2.16
Epizootiology of neoplasms in bony fish of North America. Sci Total Environ (1990) 2.13
Hysteria--a neurologist's view. Psychol Med (1986) 2.12
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Corticobasal degeneration. A clinical study of 36 cases. Brain (1994) 2.10
The metabolism of megestrol acetate (17-alpha-acetoxy-6-methylpregna-4, 6-diene-3, 20-dione) in the rabbit. Steroids (1965) 2.09
Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol (1996) 2.09
'Subcortical dementia': the neuropsychological evidence. Neuroscience (1988) 2.08
Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain (1995) 2.06
Ballistic flexion movements of the human thumb. J Physiol (1979) 2.06
Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. Mov Disord (2000) 2.06
Reciprocal inhibition between the muscles of the human forearm. J Physiol (1984) 2.05
Relationship between plasma propranolol concentration and relief of essential tremor. J Neurol Neurosurg Psychiatry (1979) 2.04
Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Modulation of motor cortical excitability by electrical stimulation over the cerebellum in man. J Physiol (1991) 2.01
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Motor cortex stimulation in intact man. 1. General characteristics of EMG responses in different muscles. Brain (1987) 1.98
Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet (1977) 1.96
Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet (1994) 1.95